354 related articles for article (PubMed ID: 34511320)
21. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
Allan JN; Shanafelt T; Wiestner A; Moreno C; O'Brien SM; Li J; Krigsfeld G; Dean JP; Ahn IE
Br J Haematol; 2022 Feb; 196(4):947-953. PubMed ID: 34865212
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Farooqui MZ; Valdez J; Martyr S; Aue G; Saba N; Niemann CU; Herman SE; Tian X; Marti G; Soto S; Hughes TE; Jones J; Lipsky A; Pittaluga S; Stetler-Stevenson M; Yuan C; Lee YS; Pedersen LB; Geisler CH; Calvo KR; Arthur DC; Maric I; Childs R; Young NS; Wiestner A
Lancet Oncol; 2015 Feb; 16(2):169-76. PubMed ID: 25555420
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.
Burger JA; Barr PM; Robak T; Owen C; Ghia P; Tedeschi A; Bairey O; Hillmen P; Coutre SE; Devereux S; Grosicki S; McCarthy H; Simpson D; Offner F; Moreno C; Dai S; Lal I; Dean JP; Kipps TJ
Leukemia; 2020 Mar; 34(3):787-798. PubMed ID: 31628428
[TBL] [Abstract][Full Text] [Related]
25. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
26. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
27. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
28. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
29. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
Kim ES; Dhillon S
Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.
Dimou M; Iliakis T; Pardalis V; Bitsani C; Vassilakopoulos TP; Angelopoulou M; Tsaftaridis P; Papaioannou P; Koudouna A; Kalyva S; Kyrtsonis MC; Panayiotidis P
Leuk Lymphoma; 2019 Dec; 60(12):2939-2945. PubMed ID: 31184241
[TBL] [Abstract][Full Text] [Related]
31. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr PM; Owen C; Robak T; Tedeschi A; Bairey O; Burger JA; Hillmen P; Coutre SE; Dearden C; Grosicki S; McCarthy H; Li JY; Offner F; Moreno C; Zhou C; Hsu E; Szoke A; Kipps TJ; Ghia P
Blood Adv; 2022 Jun; 6(11):3440-3450. PubMed ID: 35377947
[TBL] [Abstract][Full Text] [Related]
32. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.
Cuneo A; Follows G; Rigolin GM; Piciocchi A; Tedeschi A; Trentin L; Perez AM; Coscia M; Laurenti L; Musuraca G; Farina L; Delgado AR; Orlandi EM; Galieni P; Mauro FR; Visco C; Amendola A; Billio A; Marasca R; Chiarenza A; Meneghini V; Ilariucci F; Marchetti M; Molica S; Re F; Gaidano G; Gonzalez M; Forconi F; Ciolli S; Cortelezzi A; Montillo M; Smolej L; Schuh A; Eyre TA; Kennedy B; Bowles KM; Vignetti M; de la Serna J; Moreno C; Foà R; Ghia P;
Haematologica; 2018 Jul; 103(7):1209-1217. PubMed ID: 29674504
[TBL] [Abstract][Full Text] [Related]
34. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
35. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
36. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
38. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
39. Clinical Outcomes in Patients with Multi-Hit
Brieghel C; Aarup K; Torp MH; Andersen MA; Yde CW; Tian X; Wiestner A; Ahn IE; Niemann CU
Clin Cancer Res; 2021 Aug; 27(16):4531-4538. PubMed ID: 33963002
[TBL] [Abstract][Full Text] [Related]
40. Results of a Prospective Non-Interventional Post-Authorization Safety Study of Idelalisib in Germany.
Hoechstetter MA; Knauf W; Dambacher S; Hucke N; Höhne K; van Troostenburg A; Ramroth H; Abenhardt W; Rummel M
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e777-e787. PubMed ID: 35624058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
